Hong Zhu

Prof. Hong Zhu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FGFengjie Guo
Fengjie Guo
SZShijie Zhong
Shijie Zhong
YTYang Tan
Yang Tan
YYYong Yang
Yong Yang
FCFangchao Chen
Fangchao Chen
SRSong Ren
Song Ren
This study aimed to develop and validate an interpretable machine learning model for early prediction of in-hospital mortality in critically ill patients with liver cirrhosis to optimize risk stratification and individualized clinical intervention. A total of 5358 cirrhotic ICU patients were retrospectively selected from the MIMIC-IV database and randomly divided into training and internal validation cohorts at a 7:3 ratio. Twelve machine learning algorithms were constructed and compared with the conventional SAPS II score. Model performance was evaluated via AUC-ROC, and SHAP analysis was used to improve model transparency and clinical interpretability. The CatBoost model showed the best predictive performance with an AUC of 0.79, significantly superior to SAPS II (AUC = 0.75, p < 0.001). SHAP analysis identified minimum lactate, body temperature, blood urea nitrogen and white blood cell count as the top four influential predictors. Using routine clinical indicators collected within 24 h of ICU admission, this interpretable model showed better discrimination than SAPS II for predicting in-hospital mortality in critically ill patients with cirrhosis. It may assist early risk stratification, but further external validation is needed before clinical application.

15 September 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
QTQiu Tu
Qiu Tu
XLXiuyun Liu
Xiuyun Liu
XYXiaoqing Yao
Xiaoqing Yao
RLRuixue Li
Ruixue Li
GLGaojing Liu
Gaojing Liu
BZBo Zhao
Bo Zhao
Background: Severe hypoxia is a prominent character of pancreatic ductal adenocarcinoma (PDAC) microenvironment. In the process of gemcitabine based chemotherapy, PDAC cells are insulted from replication stresses co-induced by hypoxia and gemcitabine. However, PDAC cells get outstanding abilities to resist to such harsh conditions and keep proliferating, causing a major obstacle for current therapy. RETSAT (Retinol Saturase) is defined as a hypoxia convergent gene recently, with high expression in PDAC hypoxic sectors. This study aimed to explore the roles of RETSAT in replication stress resistance and hypoxia adaptation in PDAC cells, and decipher the underlying mechanism. Methods: The expression of RETSAT was examined in TCGA (The Cancer Genome Atlas), human pancreatic cancer microarray, clinical specimens and cell lines. Functions of RETSAT were studied by means of DNA fiber assay and comet assay in monolayer cultured PDAC cell lines, three dimensional spheroids, patient derived organoids and cell derived xenograft mouse models. Mechanism was investigated by using iPOND (isolate proteins on nascent DNA) combined with mass spectrometry, immunoprecipitation and immunoblotting. Results: First, we found the converse relationship of RETSAT expression and PDAC chemotherapy. That is, PDAC patients with high RETSAT expression correlated with poor survival, while ones holding low RETSAT expression were benefitted more in Gemcitabine based chemotherapy. Second, we identified RETSAT as a novel replication fork associated protein. HIF-1α signaling promotes RETSAT expression under hypoxia. Functionally, RETSAT promoted fork restarting under replication stress and maintained genomic stability. Third, we uncovered the interaction of RETSAT and R-loop unwinding helicase DDX39B. RETSAT detained DDX39B on forks to resolve R-loops, through which avoided fork damage and CHK1 initiated apoptosis. Targeting DDX39B using chemical CCT018159 sensitized PDAC cells and organoids to gemcitabine induced apoptosis, highlighting the synergetic application of CCT018159 and gemcitabine in PDAC chemotherapy. Conclusions: This study identified RETSAT as a novel replication fork protein, which functions through interacting with DDX39B mediated R-loop clearance to promote fork restarting, leading to cellular resistance to replication stresses co-induced by tumor environmental hypoxia and gemcitabine in pancreatic ductal adenocarcinoma.

1 January 2021 in Open Life Sciences
Verified
Journal Article
Open access
PDF file
RLRuixue Li
Ruixue Li
RWRenyong Wang
Renyong Wang
SZShijie Zhong
Shijie Zhong
FAFarhan Asghar
Farhan Asghar
TLTiehan Li
Tiehan Li
HZHong Zhu
Hong Zhu
Transforming growth factor (TGF)-β1 and mesenchymal stromal cells (MSCs) are two effective immunosuppressive agents for organ transplantation technology. This study aims to explore the molecular mechanism of TGF-β1-overexpressed MSCs on T cell immunosuppression. To achieve that, BM-MSCs were isolated from canine bone marrow, and their osteogenic differentiation and surface markers were detected. The TGF-β1 gene was transferred into lentivirus and modified MSCs (TGF-β1/MSCs) by lentivirus transfection. Furthermore, TGF-β1/MSCs were co-cultured with T cells to investigate their effect on differentiation and immune regulation. Results showed that TGF-β1/MSCs significantly downregulated the proportion of CD4 + CD8 + T cells in lymphocytes and significantly upregulated the proportion of CD4 + CD25 + T cells. Moreover, TGF-β1/MSCs significantly upregulated the expression of IL-10 in CD4 + T cells and downregulated the expression of IL-17A, IL-21, and IL-22. Meanwhile, interferon-γ (IFN-γ) neutralizing antibody blocked the effects of TGF-β1/MSCs on the differentiation inhibition of Th17. Overall, our results confirm the strong immunosuppressive effect of TGF-β1/MSCs in vitro and demonstrate that IFN-γ mediates the immunosuppressive effect of TGF-β1/MSC.

16 June 2023 in Frontiers in Genetics
Verified
Journal Article
Open access
LZLei Zhu
Lei Zhu
DTDong Tu
Dong Tu
RLRuixue Li
Ruixue Li
LLLin Li
Lin Li
WZWenjie Zhang
Wenjie Zhang
HZHong Zhu
Hong Zhu
Background: Pancreatic adenocarcinoma (PAAD) is among the most devastating of all cancers with a poor survival rate. Therefore, we established a zinc finger (ZNF) protein-based prognostic prediction model for PAAD patients.Methods: The RNA–seq data for PAAD were downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Differentially expressed ZNF protein genes (DE-ZNFs) in PAAD and normal control tissues were screened using the “lemma” package in R. An optimal risk model and an independent prognostic value were established by univariate and multivariate Cox regression analyses. Survival analyses were performed to assess the prognostic ability of the model.Results: We constructed a ZNF family genes-related risk score model that is based on the 10 DE-ZNFs (ZNF185, PRKCI, RTP4, SERTAD2, DEF8, ZMAT1, SP110, U2AF1L4, CXXC1, and RMND5B). The risk score was found to be a significant independent prognostic factor for PAAD patients. Seven significantly differentially expressed immune cells were identified between the high- and low-risk patients. Then, based on the prognostic genes, we constructed a ceRNA regulatory network that includes 5 prognostic genes, 7 miRNAs and 35 lncRNAs. Expression analysis showed ZNF185, PRKCI and RTP4 were significantly upregulated, while ZMAT1 and CXXC1 were significantly downregulated in the PAAD samples in all TCGA - PAAD, GSE28735 and GSE15471 datasets. Moreover, the upregulation of RTP4, SERTAD2, and SP110 were verified by the cell experiments.Conclusion: We established and validated a novel, Zinc finger protein family - related prognostic risk model for patients with PAAD, that has the potential to inform patient management.

11 November 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
RLRuixue Li
Ruixue Li
JQJianyan Qin
Jianyan Qin
ZWZiyuan Wang
Ziyuan Wang
FLFenghong Lv
Fenghong Lv
JGJiasen Guo
Jiasen Guo
YHYouguang Huang
Youguang Huang
Chemotherapy resistance is the primary cause of high mortality in patients with advanced colon cancer. The combination of small molecule compound dioscin (DIO) and traditional medicine may have a chemosensitizing effect. In this study, we reported that DIO, in combination with Oxaliplatin (L-OHP) and 5-fluorouracil (5-Fu), can effectively inhibit colon cancer cell proliferation, and co-treatment was positively related to the DIO concentration. HCT116 co-treatment with 6.4 μM L-OHP and 0.8 μM DIO significantly reduced colony formation and migration, increased apoptosis, and cell-cycle arrest in the G0/G1 and G2/M phase. DIO-assisted L-OHP significantly inhibited the xenograft model growth and exhibited low toxicity.The mRNA-sequencing combined with network pharmacological analysis suggested that the DIO sensitivity may be related to the active targets FAS, CDKN1A, ABCA1, and PPARA, which are primarily involved in regulating the cell cycle and apoptosis. Finally, our experiments suggest that DIO may enhance the L-OHP sensitivity by regulating the cell cycle through the Notch pathway.

28 February 2024 in World Journal of Gastroenterology
Verified
Journal Article
Open access
RWRen-Yong Wang
Ren-Yong Wang
JYJia-Ling Yang
Jia-Ling Yang
NXNing Xu
Ning Xu
JXJia Xu
Jia Xu
SYShao-Hua Yang
Shao-Hua Yang
HZHong Zhu
Hong Zhu
Lipid metabolism-related long noncoding RNA RP11-817I4.1 promotes fatty acid synthesis and tumor progression in hepatocellular carcinoma